Stock Analysis on Net
Stock Analysis on Net

CVS Health Corp. (NYSE:CVS)

$24.99

Income Statement
Quarterly Data

The income statement presents information on the financial results of a company business activities over a period of time. The income statement communicates how much revenue the company generated during a period and what cost it incurred in connection with generating that revenue.

Paying user area

Try for free

CVS Health Corp. pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

CVS Health Corp., consolidated income statement (quarterly data)

US$ in millions

Microsoft Excel
3 months ended: Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Products
Premiums
Services
Revenues from customers
Cost of products sold
Health care costs
Cost of revenues
Gross profit
Net investment income
Operating expenses
Restructuring charges
Opioid litigation charges
Loss on assets held for sale
Store impairments
Goodwill impairment
Operating income (loss)
Interest expense
Loss on early extinguishment of debt
Other income
Income (loss) before income tax (provision) benefit
Income tax (provision) benefit
Income (loss) from continuing operations
Loss from discontinued operations, net of tax
Net income (loss)
Net (income) loss attributable to noncontrolling interests
Net income (loss) attributable to CVS Health

Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Income statement item Description The company
Revenues from customers Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. CVS Health Corp. revenues from customers increased from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.
Operating income (loss) The net result for the period of deducting operating expenses from operating revenues. CVS Health Corp. operating income (loss) increased from Q1 2024 to Q2 2024 but then decreased significantly from Q2 2024 to Q3 2024.
Income (loss) before income tax (provision) benefit Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. CVS Health Corp. income (loss) before income tax (provision) benefit increased from Q1 2024 to Q2 2024 but then decreased significantly from Q2 2024 to Q3 2024.
Net income (loss) attributable to CVS Health The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. CVS Health Corp. net income (loss) attributable to CVS Health increased from Q1 2024 to Q2 2024 but then decreased significantly from Q2 2024 to Q3 2024.